Posted on: Wednesday, June 29, 2005

Algae farmers get green light

By Sean Hao
Advertiser Staff Writer

The state Board of Agriculture yesterday voted 6-2 in favor of allowing Big Island algae farmer Mera Pharmaceuticals Inc. to import genetically modified algae for trial production of pharmaceutical drugs.

The production of high-value drugs could be a boost for the state's $27.7 million aquaculture industry. However, Mera's plans have raised concerns about the potential health and environmental risks if the algae were accidentally released.

After about four hours of discussion at the Natural Energy Laboratory of Hawaii Authority in Kailua, Kona, the board granted Mera permission to import seven strains of genetically modified algae. Last month the board denied Mera one permit after overwhelming public opposition during an O'ahu meeting.

Scientists have weighed in on both sides of the debate over the risks while Native Hawaiians and environmental activists have generally opposed the project.

"This was a very difficult issue — no question," said board member Ted Liu, who voted in favor of Mera's application. "The staff and the board did a lot of work understanding the issues and risks," said Liu, director for the Department of Business, Economic Development and Tourism. At the "end of the day," the board had to make a decision balancing all of the interests, Liu said.

Mera's project is important for the future of Hawai'i's biotech industry, Liu said. Mera, which grows algae for nutritional supplements, wants to test the algae for the possible production of pharmaceuticals for treatment of cancer, inflammation and asthma.

Nancy Redfeather, a director for the Hawaii Genetic Engineering Action Network, said at the meeting that the board ignored scientific testimony in opposition to the project.

"I just felt like the Department of Agriculture had chosen business over protecting this precious environment," said Redfeather, whose group supports natural alternatives to genetically modified crops. "I find that very disappointing."

Mera and the company's partner Rincon Pharmaceuticals of San Diego acknowledged that the research contains risks, but contend the risk is low and will be mitigated by containment procedures.

"We're obviously pleased that the applications have been granted," said Dan Beharry, Mera's chief executive. "We are committed to going forward with this in a safe and responsible manner."

Trials could start at Mera's 4-acre facility at NELHA within months. If successful, Rincon can proceed with construction of a pilot production facility at an undecided location. Rincon would own any drugs discovered while Mera could benefit from licensing fees for its patented algae growth technology.

Reach Sean Hao at shao@honoluluadvertiser.com or 525-8093.